Trial · NCT00570739
Results by group492
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 492
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks. | Type 2 Diabetes Group:Placebo+Metformin | Baseline to 4 weeks:Pla+Met, N=128, Col+Met N=129 | -0.38 | Standard Error 0.044 | Percentage of change in HbA1c |
| Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks. | Type 2 Diabetes Group:Colesevelam+Metformin | Baseline to 4 weeks:Pla+Met, N=128, Col+Met N=129 | -0.53 | Standard Error 0.044 | Percentage of change in HbA1c |
| Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks. | Type 2 Diabetes Group:Placebo+Metformin | Baseline to 8 weeks:Pla+Met, N=123, Col+Met N=125 | -0.67 | Standard Error 0.055 | Percentage of change in HbA1c |
| Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks. | Type 2 Diabetes Group:Colesevelam+Metformin | Baseline to 8 weeks:Pla+Met, N=123, Col+Met N=125 | -0.84 | Standard Error 0.055 | Percentage of change in HbA1c |
| Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks. | Type 2 Diabetes Group:Placebo+Metformin | Baseline to 12 weeks:Pla+Met, N=115, Col+Met N=123 | -0.86 | Standard Error 0.062 | Percentage of change in HbA1c |
| Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks. | Type 2 Diabetes Group:Colesevelam+Metformin | Baseline to 12 weeks:Pla+Met, N=115, Col+Met N=123 | -1.05 | Standard Error 0.059 | Percentage of change in HbA1c |
| Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks. | Type 2 Diabetes Group:Placebo+Metformin | Baseline to 16 weeks:Pla+Met, N=118, Col+Met N=122 | -0.92 | Standard Error 0.064 | Percentage of change in HbA1c |
| Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks. | Type 2 Diabetes Group:Colesevelam+Metformin | Baseline to 16 weeks:Pla+Met, N=118, Col+Met N=122 | -1.17 | Standard Error 0.063 | Percentage of change in HbA1c |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group: Placebo+Metformin | baseline to 4 weeks Pla+Met N=130, Col+Met N=131 | -19.0 | Standard Error 2.31 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group:Colesevelam+Metformin | baseline to 4 weeks Pla+Met N=130, Col+Met N=131 | -24.0 | Standard Error 2.30 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group: Placebo+Metformin | baseline to 8 weeks:Pla+Met N=122, Col+Met N=126 | -24.3 | Standard Error 1.97 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group:Colesevelam+Metformin | baseline to 8 weeks:Pla+Met N=122, Col+Met N=126 | -27.6 | Standard Error 1.94 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group: Placebo+Metformin | baseline to 12 weeks:Pla+Met N=121, Col+Met N=125 | -27.3 | Standard Error 2.21 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group:Colesevelam+Metformin | baseline to 12 weeks:Pla+Met N=121, Col+Met N=125 | -28.4 | Standard Error 2.18 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group: Placebo+Metformin | baseline to 16 weeks:Pla+Met N=119, Col+Met N=124 | -28.0 | Standard Error 2.21 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group:Colesevelam+Metformin | baseline to 16 weeks:Pla+Met N=119, Col+Met N=124 | -30.5 | Standard Error 2.16 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group: Placebo+Metformin | baseline to 16wks LOCF:Pla+Met N=137,Col+Met N=138 | -25.9 | Standard Error 2.19 | mg/dL |
| Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group:Colesevelam+Metformin | baseline to 16wks LOCF:Pla+Met N=137,Col+Met N=138 | -28.0 | Standard Error 2.18 | mg/dL |
| Fasting Insulin When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group:Placebo+Metformin | Baseline to 4 weeks:Pla+Met, N=127, Col+Met N=127 | -2.124 | Standard Error 0.7219 | uIU/mL |
| Fasting Insulin When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks | Type 2 Diabetes Group:Colesevelam+Metformin | Baseline to 4 weeks:Pla+Met, N=127, Col+Met N=127 | -2.427 | Standard Error 0.7219 | uIU/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00570739/results